A multifunctional nanoplatform, GS@DFP, is designed to cross the blood-brain barrier and target glioblastoma by combining ROS-responsive drug release, mitochondrial disruption, and suppression of astrocyte-to-tumor mitochondrial transfer.
Editorial Team•2026-01-01
9 min read
